SPARC logo

Sun Pharma Advanced Research Company Limited Stock Price

NSEI:SPARC Community·₹69.6b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author

SPARC Share Price Performance

₹214.48
60.03 (38.87%)
₹214.48
60.03 (38.87%)
Price ₹214.48

SPARC Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet with acceptable track record.

3 Risks
2 Rewards

Sun Pharma Advanced Research Company Limited Key Details

₹18.8b

Revenue

₹299.5m

Cost of Revenue

₹18.5b

Gross Profit

₹3.0b

Other Expenses

₹15.5b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
47.86
98.41%
82.65%
41.5%
View Full Analysis

About SPARC

Founded
2006
Employees
279
CEO
Anilkumar Raghavan
WebsiteView website
sparc.life

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Recent SPARC News & Updates

Recent updates

No updates